AAV Mini-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy: A Phase Ib Trial

Pediatric ambulatory male participants with a genetic Duchenne muscular dystrophy diagnosis and receiving stable glucocorticoids received a single intravenous low-dose or high-dose fordadistrogene movaparvovec.